However, non-responders with HR-negative cancer or high expression levels of HER2 or Ki67 were more likely to benefit from the addition of pyrotinib, aligning with previous reports.10 This indicates that patients with more advanced cancer may be better candidates for a response-guided strategy. Here, ERBB2 is linked to cancer.